In a down economy, women’s health company announces growth
(WAYNE, PA) At a time
when industry retrenchment, lay-offs and
even bail outs dominate the news, a
specialty pharmaceutical company located
outside Philadelphia is experiencing growth.
This week, FemmePharma Global
Healthcare, Inc announces the establishment
of a new division, FemmePharma Mental
Healthcare, Central
Nervous System, that will focus on
central nervous system (CNS) disorders in
women.
“We are energized to
expand our commitment in women’s health
even at a time when the pharmaceutical
industry is retreating in this area,” says FemmePharma’s
President and CEO Gerianne Tringali DiPiano.
“For FemmePharma, these are times which
provide a wealth of opportunities in women’s
health.”
Since its establishment
in 1996, FemmePharma has focused on women’s
gynecological health issues, including urinary
incontinence and fibrocystic breast disease.
With its expansion into CNS, that focus
is growing to develop treatments particularly
for depression (including postpartum
depression), anxiety disorders, eating
disorders and neuropathic pain specific to
women.
“We know that women
respond differently than men to medications
for depression,” Tringali DiPiano says,
referring to a study published in 2006 in the
Journal of Affective Disorders.
“And this is just one example.
Understanding and developing treatments
that respond to women’s unique health
challenges is FemmePharma’s mission so our
expansion into CNS disorders in women
represents a natural progression,” Tringali
DiPiano says.
While FemmePharma
continues to invest and grow, the
pharmaceutical industry in general is
withdrawing.
In April of this year, a Wall Street
Journal website estimated that as many as
25,000 pharmaceutical jobs were expected to be
eliminated in 2008.
And in October, Wyeth announced that it
would eliminate discovery work in women’s
health while reducing its therapeutic areas
from 14 to six.
Tringali DiPiano says
this represents a concern for her personally
while providing an exciting opportunity for
her company.
“The gap in developing
treatments unique to women is widening even
though there are significant unmet needs,”
Tringali DiPiano says.
“Without question our expansion into
CNS is an indication of our continued growth
and commitment to women and their unique
health needs.”
The women’s health sector
represents an estimated $116 billion market by
the year 2010, according to a report by
Research and Markets.com.
For more information, call Ed Weirauch at 302-528-8847 or email him
at
edweirauch@earthlink.net.
Back to top
FemmePharma Founder honored by Pharma Voice
(WAYNE, PA)
Gerianne Tringali DiPiano, President, CEO and founder
of FemmePharma in Wayne, PA, has been named
one of the top entrepreneurs by the
publication Pharma Voice.
Among the 12 individuals honored
nationally, Tringali DiPiano is one of only
two women.
PharmaVoice editors
describe Tringali DiPiano as a
“forward-thinking risk taker who has not only
carved out a niche in the life sciences by
creating a whole new business (FemmePharma),
but has steered her company to new heights.”
Tringali DiPiano serves
as the lead inventor on FemmePharma patents
and
developer of drug
formulations for women’s health products that
minimize side effects without sacrificing
efficacy in the areas of urinary incontinence,
fibrocystic breast disease and dysfunctional
uterine bleeding.
She’s also the lead fundraiser for the
company.
“Improving women’s health
is my motivator,” she says; “our work is
driven by our desire to develop products that
will ultimately improve the quality of life
for women.”
Tringali DiPiano was
named one of Pennsylvania’s Best 50 Women in
Business by Governor Ed Rendell and she serves
as Executive Vice-President on the Board of
Trustees for Drexel University.
For more information, call Ed Weirauch at 302-528-8847 or email him
at
edweirauch@earthlink.net.
Back to top
Novel Investigational Drug May Help The 26 Million American Women Suffering From Breast Pain
--Clinical Trial for Fibrocystic Breast Disease Being Conducted Nationwide--
WAYNE, PA – June 27, 2007—A clinical trial for a much needed
treatment option for pain associated with fibrocystic breast disease, is
in progress nationwide. The severely debilitating symptoms such as
breast pain, affects about 26 million women in the United States alone
but is often left untreated leaving women feeling hopeless.
As many as 50% of American women talk to their physician about breast
pain including swelling, tenderness and lumps that increase prior and
during menstruation and may continue for several days. The pain is not
only physical. Psychological stress is often associated with undergoing
mammograms, ultrasound scans and breast biopsies, techniques frequently
utilized by physicians to rule out other diseases of the breast.
“Breast pain associated with fibrocystic breast disease can be
physically impairing, leaving women unable to cope with basic daily
functions, yet 85% of women don’t receive treatment,” said Gerianne
Tringali DiPiano, President and CEO of FemmePharma Global Healthcare,
the company sponsoring the study. “We hope news of this trial will
compel women with breast pain associated with fibrocystic breast disease
who have been previously diagnosed to seek a study center in their
area.”
Physicians at centers nationwide will enroll women who have breast
pain associated with fibrocystic breast disease.
“The trial allows us to assess a new dosage form of an active
pharmaceutical ingredient with a demonstrated safety and efficacy
profile. We expect that the new dosage forms will provide a new
treatment option for this very important disease state,” added Bruce J.
Levine MD, FACOG, and investigator of the trial.
For more information about the clinical trial and enrollment please
visit the Clinical Trial section of FemmePharma Global Healthcare’s
website at
www.femmepharma.com.
About Breast Pain Associated with Fibrocystic Breast Disease
Breast pain can impair a woman’s ability to work, participate in her
daily activities, embrace a child or have an intimate relationship with
her partner. In addition, breast pain frequently causes increased
anxiety and stress in a woman’s life as a result of dealing with pain
each month.
Approximately 15% of women who experience breast pain require
prescription medication. Currently there is only one FDA approved
prescription medication for pain associated with fibrocystic breast
disease. However, this medication typically produces unwanted systemic
side effects, which often causes women to stop their necessary
treatment. In many cases, women are sent home and told to ice their
breasts or purchase a tighter fitting brassiere leaving them feeling
hopeless.
About FemmePharma Global Healthcare, Inc.
FemmePharma Global Healthcare, Inc. is committed to improving the health
of women and is exploring an innovative, investigational drug that
provides adequate relief with minimal unwanted side effects for women
suffering from pain associated with fibrocystic breast disease.
Founded in 1996, FemmePharma Global Healthcare is focused on
developing safe and effective drugs minimizing or eliminating the side
effects associated with many drug therapies by designing treatments in a
way that suits the female anatomy and physiology. The company has
already scored great success in the development of a treatment for
endometriosis through Phase 2. As a result, KV Pharmaceuticals bought
the global rights and continues its development of the product.
Other current endeavors include a product to treat urinary
incontinence in Phase 2 clinical trials, and products to treat
dysmenorrhea and dysfunctional uterine bleeding in preclinical
development.
For more information, call Carrie Yamond at 212-845-4259.
Back to top
FemmePharma CEO Gerianne Tringali DiPiano Named One of “Pennsylvania’s Best 50 Women in Business”
Wayne, PA… Gerianne Tringali DiPiano, founder, president and CEO of FemmePharma Global Healthcare Inc., a women’s pharmaceutical company, was recently named one of “Pennsylvania’s Best 50 Women in Business” by Gov. Edward G. Rendell and five Pennsylvania business journals.
The award is given to women who are not only business leaders, but who are making valuable contributions to Pennsylvania’s future through their efforts to positively influence the state’s economic future. “Their substantive efforts are creating new opportunities for our residents, growing the state’s economy, and improving the quality of life in our communities,” said Gov. Rendell.
“I am thrilled to have been awarded this distinction and to be included in such an accomplished group of women,” Ms. Tringali DiPiano said. “FemmePharma has a team of incredibly talented individuals who are passionate about helping to bring about healing and improve the quality of life for women with diseases and conditions across the globe. Every time I meet a women with one of these conditions I am further encouraged to move forward with this mission and to alleviate women’s pain and suffering.”
Ms. Tringali DiPiano founded FemmePharma Global Healthcare in 1996 following nearly two decades of experience in medical affairs, marketing, new product development, and global licensing and business development with major pharmaceutical companies. FemmePharma is dedicated to developing products that improve women’s health with treatments for endometriosis, urinary incontinence, fibrocystic breast disease, HIV, dysfunctional uterine bleeding, and other conditions.
Through her company Ms. Tringali DiPiano has given hope to millions of women who were unsatisfied with the current efforts of large pharmaceutical companies. By going beyond the current fare of treatments for female disorders, she has opened up a new world for sufferers of endometriosis and is looking to similarly create hope for those suffering with chronic breast pain, urinary incontinence and other painful conditions.
FemmePharma recently opened up clinical trials at 12 sites across the U.S. for an innovative new treatment for chronic breast pain that could provide relief to more than 26 million women, without the unwanted side effects of current treatment options.
The Central Penn Business Journal, along with the Pennsylvania Department of Community and Economic Development and four other business journals honored these women at an awards reception on May 21 and award recipients will also be profiled in the
Central Penn Business Journal, the Northeastern Pennsylvania Business Journal, the
Eastern Pennsylvania Business Journal, the Pittsburgh Business Times and
Pennsylvania Business Central.
An independent panel of judges selected the top 50 candidates based on dedication to business growth, professional and personal accomplishments, community involvement, and advocacy for women in business.
Pennsylvania’s Best 50 Women In Business is a program of the Pennsylvania Department of Community and Economic Development and the
Central Penn Business Journal, in conjunction with the Northeastern Pennsylvania Business Journal, the
Eastern Pennsylvania Business Journal, the Pittsburgh Business Times and
Pennsylvania Business Central and is sponsored by Citizens Bank, D&E Communications, Highmark, Inc., Millers Mutual Group, Messiah College, and WHP-TV and the new CW15.
For more information, visit FemmePharma’s website at www.fpghc.com or call 610-995-0801.
FEMMEPHARMA GLOBAL HEALTHCARE CEO SELECTED AS ONE OF 25 WOMEN OF DISTINCTION OF THE GREATER PHILADELPHIA BUSINESS COMMUNITY
Gerianne Tringali DiPiano Will be Honored at Dec. 6 Award Celebration
Wayne, PA…FemmePharma Global Healthcare is pleased to announce that company president, CEO, and founder, Gerianne Tringali DiPiano, has been selected as a Women of Distinction by The Philadelphia Business Journal and the National Association of Women Business Owners. DiPiano was selected for her commitment to developing treatment options for diseases and disorders affecting women. DiPiano is one of 25 dynamic women who will be honored at the Ninth Annual Women of Distinction Banquet, which will take place on Wednesday, December 6, 2006 at the Sheraton Center City. The 2006 Women of Distinction will also be profiled in a special section of the Philadelphia Business Journal’s December 8 issue.
Read Gerianne Tringali DiPiano's profile for the 2006 Women of Distinction award here.
About Women of Distinction
The Women of Distinction award celebrates female professionals on their way to becoming future legends in their respective fields and businesses. A diverse judging panel of industry experts selected award winners from a pool of over 200 nominations. All candidates were evaluated in three categories: professional accomplishments, community involvement, and awards and milestones. The honorees represent women from every industry and profession who have made a positive mark on the region professionally and through community service.
"This program and event is one of my favorites. It is an honor to congratulate these outstanding high achieving women," said Lyn Kremer, Publisher of the Philadelphia Business Journal.
“Being selected for the Women of Distinction award is truly an honor. It confirms the significance and impact of what we are striving to accomplish at FemmePharma,” DiPiano said.
About Gerianne Tringali DiPiano
DiPiano founded FemmePharma Global Healthcare in 1996. The company is dedicated to developing products that improve women’s health with treatments for endometriosis, urinary incontinence, fibrocystic breast disease, HIV, dysfunctional uterine bleeding, and other conditions. After successfully completing Phase 2 studies for its treatment of endometriosis, the product was acquired by KV Pharmaceutical which will continue its development and bring the drug to market.
Earlier this year, FemmePharma opened an Investigational New Drug Application for the treatment of breast pain. Clinical trials will begin in early 2007.
Tringali- DiPiano serves on the Boards of Drexel University, Women’s Law Project, Country Day School of the Sacred Heart, Temple University School of Allied Health Professions, Drexel University School of Public Health, Advisory Board of the Pharmaceutical MBA Program, Academic Affairs Committee, Corporate Advisory board of the Society of Gynecological Investigation and on the Editorial Advisory Board of the Biotechnology Healthcare publication. She is a recipient of the Southeastern Pennsylvania Regional Biotechnology Award and the Iris F. Newman Award (Ben Franklin Technology Awards). She has been a Life Science Finalist three times for the Ernst and Young Entrepreneur of the Year Award and been cited as a person to watch by Philadelphia Magazine and the Main Line Times. In addition, the Eastern Technology Council has saluted FemmePharma as a Company to Watch through its annual Enterprise Awards.
Tringali-DiPiano believes strongly in sharing her knowledge with students and has guest lectured and been a conference moderator for University of Pennsylvania School of Law, Temple University Fox School of Business, Temple University Institute for Entrepreneurship, and the University of the Sciences. She serves on the corporate advisory board of the Society of Gynecological Investigation and on the editorial advisory board of the Biotechnology Healthcare publication. She has shared her professional insights and experience as a guest speaker for the Pennsylvania Biotechnology Association and the Greater Philadelphia Venture Group.
Tringali-DiPiano is actively involved in the surrounding community, serving as a trustee of Drexel University where she sits on the Academic Affairs Committee. She also serves as a trustee of Country Day School of the Sacred Heart.
Because her concern for fair treatment of women extends beyond healthcare, she is a trustee of the Women’s Law Project, a nonprofit public interest legal advocacy group. She is a strong supporter of local and national charities including the MS Society, which has honored her with the MS Leadership Award.
For more information about the FemmePharma Global Healthcare, which is based in Wayne, PA, visit www.fpghc.com or call 610-995-0801 to obtain information.
Back to top
Gerianne Tringali-DiPiano Bets the Femme Pharma
In 1996 Gerianne Tringali-DiPiano had more than two decades of experience as a pharmaceutical executive. She saw how the women’s health industry had focused on contraception and hormone replacement therapy, but had left a yawning void by virtually ignoring other diseases and disorders. She decided she could—and would—do something about it.
Read
more>>
Back to top
FemmePharma Global Healthcare, Inc. Opens Investigational New Drug Application for Treatment of Breast Pain
Wayne, PA…FemmePharma Global Healthcare, Inc., a suburban Philadelphia-based pharmaceutical company focusing on developing treatments for diseases and disorders suffered by women opened an Investigational New Drug application for the treatment of breast pain. Clinical trials are expected to commence in the fourth quarter of 2006.
The development of a treatment to alleviate breast pain comes at the heels of the company’s previous success at developing a treatment that lessens the severe discomfort caused by endometriosis. FemmePharma Global Healthcare developed its treatment for endometriosis using a unique, patented platform technology that eliminates systemic side effects by concentrating a small but effective amount of the drug directly to a targeted area of the disease or disorder.
The company is now engineering its patented platform technology to develop a topical cream to treat breast pain because side effects caused by the few current treatment options are seriously objectionable. “If a women goes to her physician today for medication to help relieve breast pain she likely will be faced with several inferior choices: an FDA-approved prescription medication that typically causes unpalatable side effects like facial hair growth, weight gain and acne; or an over-the-counter pain reliever that does not address the underlying causes of breast pain,” said Gerianne Tringali DiPiano, President and CEO of FemmePharma Global Healthcare.
“The lack of an effective and safe treatment for breast pain is why FemmePharma Global Healthcare has developed a convenient, topical treatment that should diminish side effects and achieve efficacy,” added Dr. Peter Mays, Vice President, Pharmaceutical Development of FemmePharma Global Healthcare.
On the whole, breast pain is a widespread problem. Roughly 26 million women complain of the disorder, and about 15 percent of women experience symptoms severe enough to warrant medication. Breast pain remains seriously debilitating and can cause its victims to miss work, withdraw from everyday activities, and recoil from intimacy. Sometimes the pain is so severe that a woman may even avoid hugging her children.
FemmePharma Global Healthcare’s efforts to create an effective treatment that yields no harmful side effects could offer long-awaited relief for those women who suffer sharp, stabbing, burning, chronic pain.
According to Tringali DiPiano, female patients are often given cursory, ineffective advice on how to cope with the pain or are treated as if the disorder is a phantom pain. “Breast pain produces stress and anxiety as women are concerned about the underlying causes of the pain. Even more concerning, breast pain is a leading reason why physicians overprescribe mammography for young women,” said Tringali DiPiano.
Founded in 1996, FemmePharma Global Healthcare is focused on developing safe and effective drugs minimizing or eliminating the side effects associated with many drug therapies by designing treatments in a way that suits the female anatomy. The company has already scored great success with developing a safe and effective treatment for endometriosis. After successfully completing Phase 2 studies for this product, it was acquired by KV Pharmaceutical who will continue its development and bring the drug to market. Other current endeavors include a product to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development.
For more information, visit www.fpghc.com
or call 610-995-0801.
Back to top
Baltimore Native Returns to Her Roots Seeking Investors and Investigators for New Drug Protocol
Wayne, PA…FemmePharma Global Healthcare, Inc., a Philadelphia-area pharmaceutical company that focuses on developing treatments for diseases and disorders suffered by women, is reaching out to investors and investigators in the Baltimore area to discuss its new treatment for breast pain. The company recently was given permission by the FDA to open an Investigational New Drug (IND) Application to commence a Phase 2 clinical trial. FemmePharma president and CEO, Gerianne Tringali DiPiano, who was born and raised in suburban Baltimore and is the daughter of an accomplished Baltimore area entrepreneur, Joseph C. Tringali, is targeting the region because of the accelerated growth of bioscience companies and the state’s increasingly favorable entrepreneurial climate. Now that the company’s IND is open, clinical trials should begin by the fourth quarter of 2006 and the company will be seeking medical talent and subjects from Baltimore.
Maryland: A Biotech Industry Leader
“Maryland, and the Baltimore region specifically, are biotech hotspots offering an abundance of talent,” stresses Tringali DiPiano. A 2004 study prepared by the Milken Institute ranked Maryland second in the nation for biopharmaceutical innovations. With more than 300 biotech companies and an annual payroll of $2.1 billion, Maryland is on the bioscience fast track. “I am confident that this region is the right place to begin clinical trials. As the epicenter of biotech activity, FemmePharma will have access to office space, laboratories, manufacturing, employees and expertise, factors that are critical to furthering FemmePharma’s research interests,” added Tringali DiPiano.
A Therapy to Improve Human Health
FemmePharma’s foray into treating breast pain comes at the heels of the company’s previous success at developing a treatment that lessens the severe discomfort caused by endometriosis. The treatment for endometriosis was developed from a unique, patented platform technology that eliminates systemic side effects by concentrating a small but effective amount of the drug directly to a targeted area of the disease or disorder.
The company is engineering its patented platform technology to develop a topical cream to treat breast pain that will eliminate the side effects caused by the few available treatments. “Physicians are limited in how they treat breast pain. They can prescribe an FDA-approved prescription medication that typically causes facial hair growth, weight gain and acne; or an over-the-counter pain reliever that does not address the underlying causes of breast pain,” said Tringali
DiPiano.
Breast Pain: A Common Problem
Breast pain is a widespread problem. Roughly 26 million women in the United States are plagued by the disorder, and about 15 percent of sufferers experience symptoms severe enough to warrant medication. Breast pain is debilitating and can cause its victims to miss work, withdraw from everyday activities, and recoil from intimacy. Sometimes the pain is so severe that a woman may even avoid hugging her children. But the condition is not always treated with concern. “Breast pain is sometimes diagnosed as phantom pain and is one of the leading reasons physicians over-prescribe mammography exams for young women,” said Tringali DiPiano.
FemmePharma Global Healthcare’s efforts to create an effective treatment that yields no harmful side effects could offer long-awaited relief for millions of women.
About FemmePharma
Founded by Tringali DiPiano in 1996, FemmePharma Global Healthcare’s goal is to develop safe and effective drugs that minimize or eliminate the side effects associated with existing drug therapies and ensuring that new therapies suit the female anatomy. The company has a proven track record. After successfully completing Phase 2 studies for its treatment of endometriosis, the product was acquired by KV Pharmaceutical which will continue its development and bring the drug to market. Other current endeavors include a therapy to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development.
For more information about the clinical trials in the Baltimore region, visit
www.fpghc.com or call 610-995-0801 to obtain information.
Back to top
CROSSING THE DELAWARE TO WOO INVESTORS & INVESTIGATORS
Pharmaceutical Company Searches for “HOT” Biotech Climate
Wayne, PA…FemmePharma Global Healthcare, Inc., a Philadelphia-area pharmaceutical company that focuses on developing treatments for diseases and disorders suffered by women, is reaching out to investors and investigators in New Jersey to discuss its new treatment for breast pain. The company was recently given permission by the FDA to open an Investigational New Drug (IND) Application. FemmePharma president and CEO, Gerianne Tringali DiPiano, plans to conduct clinical trials in New Jersey because of the state’s accelerated growth of bioscience companies and its increasingly favorable business climate. Now that the company’s IND is open, clinical trials should begin by the fourth quarter of 2006 and the company will be seeking medical talent and subjects from New Jersey.
New Jersey: Leading the Industry
According to Tringali DiPiano, “New Jersey is on its way to becoming a biotech hotspot.” A 2004 BIO-Batelle Study, a comprehensive analysis that quantifies the scope and impact of bioscience employment in all 50 states, noted that “New Jersey has nurtured the key factors that appear to influence a state's ability to grow bioscience employment. These include the degree of involvement by research institutions, available capital, access to facilities and equipment, a stable and supportive tax and regulatory environment and a long-term perspective.” Tringali DiPiano added, “I am confident that this region is the right place to begin clinical trials. As the epicenter of biotech activity, FemmePharma will have access to office space, laboratories, manufacturing, employees and expertise --- factors that are critical to furthering FemmePharma’s research interests.”
A Therapy to Improve Human Health
FemmePharma’s foray into treating breast pain comes at the heels of the company’s previous success at developing a treatment that lessens the severe discomfort caused by endometriosis. The treatment for endometriosis was developed from a unique, patented platform technology that eliminates systemic side effects by concentrating a small but effective amount of the drug directly to a targeted area of the disease or disorder.
The company is engineering its patented platform technology to develop a topical cream to treat breast pain that will eliminate the side effects caused by the few available treatments. “Physicians are limited in how they treat breast pain. They can prescribe an FDA-approved prescription medication that typically causes facial hair growth, weight gain and acne; or an over-the-counter pain reliever that does not address the underlying causes of breast pain,” said Tringali DiPiano.
Breast Pain: A Common Problem
Breast pain is a widespread problem. Roughly 26 million women are plagued by the disorder, and about 15 percent of sufferers experience symptoms severe enough to warrant medication. Breast pain is debilitating and can cause its victims to miss work, withdraw from everyday activities, and recoil from intimacy. Sometimes the pain is so severe that a woman may even avoid hugging her children. But the condition is not always treated with concern. “Breast pain is sometimes diagnosed as phantom pain and is one of the leading reasons physicians over-prescribe mammography exams for young women,” said Tringali DiPiano.
FemmePharma Global Healthcare’s efforts to create an effective treatment that yields no harmful side effects could offer long-awaited relief for millions of women.
About FemmePharma
Founded by Tringali DiPiano in 1996, FemmePharma Global Healthcare’s goal is to develop safe and effective drugs that minimize or eliminate the side effects associated with existing drug therapies and ensuring that new therapies suit the female anatomy. The company has a proven track record. After successfully completing Phase 2 studies for its treatment of endometriosis, the product was acquired by KV Pharmaceutical which will continue its development and bring the drug to market. Other current endeavors include a therapy to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development.
For more information about the clinical trials in the Baltimore region, visit
www.fpghc.com or call 610-995-0801 to obtain information.
Back to top
|
|
